Abstract
Background Recent studies in selected populations suggest that impaired venous return may affect brain health. We examined associations of right heart structure and function with cognition and MRI markers of brain health in a community-based cohort.
Methods The Multi-Ethnic Study of Atherosclerosis (MESA) is a longitudinal cohort study of individuals 45 to 84 years of age who were free of clinically apparent cerebrovascular or cardiovascular disease at baseline in 2000-2002. From echocardiograms performed at Exam 6 during 2016-2018, we measured: right atrial pressure and end-systolic area; pulmonary artery systolic pressure; and right ventricular free wall strain, fractional area change, and end-diastolic area. Outcome variables were the Cognitive Assessment Screening Instrument, Digit Span, and Digit Symbol Coding tests and MRI-determined volumes of total white matter, total gray matter, and white matter hyperintensity -- as well as fractional anisotropy. Cognitive measures were obtained at Exam 6, and MRI measures, within a median of 18 months of echocardiograms. Covariates were demographics, APOE-ε4 allele status, vascular risk factors, and echocardiographic markers of left heart function. We used general linear models to examine associations between each exposure and outcome variable.
Results In 1,913 participants with cognitive testing and echocardiography data, we found no associations between any of the echocardiographic exposure variables and worse scores on any of the cognitive tests. Similarly, in 1,035 participants with echocardiography and MRI data, we found no associations between any of the echocardiographic exposure variables and any of the MRI variables.
Discussion We found no associations in this cohort of right heart structure and function with cognition or brain MRI measures. These findings do not support the hypothesis that right heart dysfunction impedes venous return sufficiently to adversely affect brain health among people without clinically apparent heart failure.
Competing Interest Statement
Financial disclosures for Hooman Kamel: a PI role in the ARCADIA trial, which received in-kind study drug from the BMS-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics; a Deputy Editor role for JAMA Neurology; clinical trial steering/executive committee roles for the STROKE-AF (Medtronic), LIBREXIA-AF (Janssen), and LAAOS-4 (Boston Scientific) trials; consulting or endpoint adjudication committee roles for AbbVie, AstraZeneca, Athos Therapeutics, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk; and household ownership interests in TETMedical, Spectrum Plastics Group, and Ascential Technologies.
Funding Statement
This research was supported by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 and grants R01HL127659 and R01HL127028 from the National Heart, Lung, and Blood Institute, R01AG054069 from the National Institute on Aging, and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from the National Center for Advancing Translational Sciences.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided written, informed consent for participation in MESA, and institutional review boards at all participating MESA sites approved this study
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
